ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/03/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Descrição da marca
The mark consists of the turquoise word "ASCENDIS" under which is the grey word "PHARMA" next to a polygon broken by a white curved band in which the top is turquoise and the bottom is blue.
Titulares
Representantes
Eric T. Fingerhut Dykema Gossett PLLC
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides
Classe 42
Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology
Classe 45
Licensing of industrial property; legal services
Histórico de despachos e eventos da marca no USPTO.
72 publicações encontradas
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/03/2026
NEW REPRESENTATIVE AT IB RECEIVED
10/03/2024
FINAL DECISION TRANSACTION PROCESSED BY IB
01/08/2022
FINAL DISPOSITION NOTICE SENT TO IB
13/07/2022
FINAL DISPOSITION PROCESSED
13/07/2022
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/05/2022
REGISTERED-PRINCIPAL REGISTER
01/02/2022
NEW REPRESENTATIVE AT IB RECEIVED
24/12/2021
NOTIFICATION PROCESSED BY IB
23/11/2021
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/11/2021
PUBLISHED FOR OPPOSITION
16/11/2021
NEW REPRESENTATIVE AT IB RECEIVED
28/10/2021
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/10/2021
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/10/2021
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/10/2021
APPROVED FOR PUB - PRINCIPAL REGISTER
13/10/2021
TEAS/EMAIL CORRESPONDENCE ENTERED
12/10/2021
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/10/2021
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/10/2021
NOTIFICATION OF FINAL REFUSAL EMAILED
09/07/2021
FINAL REFUSAL E-MAILED
09/07/2021
FINAL REFUSAL WRITTEN
09/07/2021
ASSIGNED TO EXAMINER
10/06/2021
TEAS/EMAIL CORRESPONDENCE ENTERED
16/03/2021
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/03/2021
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/03/2021
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/03/2021
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/03/2021
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
15/03/2021
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/03/2021
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/03/2021
TEAS CHANGE OF OWNER ADDRESS RECEIVED
15/03/2021
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
15/03/2021
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
15/03/2021
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/09/2020
NON-FINAL ACTION E-MAILED
14/09/2020
NON-FINAL ACTION WRITTEN
14/09/2020
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
18/06/2020
ASSIGNED TO LIE
03/06/2020
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
21/11/2019
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/07/2019
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/06/2019
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
19/06/2019
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
09/05/2019
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
19/10/2018
LETTER OF SUSPENSION E-MAILED
19/10/2018
SUSPENSION LETTER WRITTEN
19/10/2018
DATA MODIFICATION COMPLETED
01/10/2018
TEAS/EMAIL CORRESPONDENCE ENTERED
28/09/2018
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/09/2018
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/09/2018
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/09/2018
NON-FINAL ACTION E-MAILED
14/09/2018
NON-FINAL ACTION WRITTEN
14/09/2018
TEAS/EMAIL CORRESPONDENCE ENTERED
17/08/2018
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/08/2018
ASSIGNED TO LIE
16/08/2018
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/07/2018
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/07/2018
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/07/2018
REFUSAL PROCESSED BY IB
02/03/2018
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/02/2018
REFUSAL PROCESSED BY MPU
09/02/2018
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/02/2018
NON-FINAL ACTION WRITTEN
06/02/2018
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
02/02/2018
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/01/2018
NON-FINAL ACTION WRITTEN
29/01/2018
APPLICATION FILING RECEIPT MAILED
23/01/2018
ASSIGNED TO EXAMINER
19/01/2018
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/01/2018
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/01/2018
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.